Novartis | NVS - Creditori Commerciali





Creditori Commerciali Cambiamento Data
AbbVie USD 3.59B 28.65B 2025-12
Amgen USD 19.52B 1.37B 2026-03
AstraZeneca USD 22.51B 2.78B 2026-03
Bausch Health Companies USD 593M 7M 2026-03
Biogen USD 358.5M 73.5M 2026-03
Bristol-Myers Squibb USD 4.23B 659M 2026-03
Canopy Growth CAD 19.96M 1.83M 2025-12
Corcept Therapeutics USD 33.31M 7.14M 2026-03
Drreddys Laboratories INR 454.04M 854K 2025-12
Eli Lilly USD 5.03B 350M 2026-03
Gilead Sciences USD 645M 70M 2026-03
GlaxoSmithKline GBP 14.34B 1.05B 2026-03
Glaxosmithkline GBP 20.72B 346.14M 2025-12
J&J USD 10.46B 1.53B 2026-03
Merck USD 3.86B 541M 2026-03
Novartis USD 4.32B 134M 2026-03
Novartis USD 4.46B 99M 2025-12
Pacira USD 14.01M 1.14M 2026-03
Perrigo USD 434.8M 39.7M 2026-03
Pfizer USD 4.51B 734M 2026-03
Phibro Animal Health USD 129.64M 3.65M 2026-03
Prestige Brands USD 42.95M 1.02M 2025-12
Roche Holding CHF 5.78B 1.27B 2025-12
Sanofi EUR 22.71B 219M 2026-03
Sanofi EUR 22.93B 2.89B 2025-12
Supernus Pharmaceuticals USD 10.17M 97.63M 2026-03
Zoetis USD 507M 20M 2026-03